BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32248654)

  • 1. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
    Urick ME; Bell DW
    Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
    Urick ME; Yu EJ; Bell DW
    Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
    Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
    Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of tumor suppressors changes the endometrial tumor spectrum.
    Mayo LD
    EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search for biomarkers and potential drug targets for uterine serous endometrial cancer.
    Dinoi G; Mariani A; Martinelli E; Ciucci A; Zannoni GF; Weaver AL; Keeney GL; Vasmatzis G; Anastasiadis PZ; Fanfani F; Scambia G; Gallo D
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1647-1658. PubMed ID: 33754208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.
    Liu L; Jiang H; Wang X; Wang X; Zou L
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs.
    Devor EJ; Hovey AM; Goodheart MJ; Ramachandran S; Leslie KK
    Oncol Rep; 2011 Oct; 26(4):995-1002. PubMed ID: 21725615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
    Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
    EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Thyroid Receptor Interacting Protein 6 by MicroRNA-589-5p Inhibits Cell Proliferation, Migration, and Invasion in Endometrial Carcinoma.
    Wang Y; Dong L; Liu Y
    Cancer Biother Radiopharm; 2019 Oct; 34(8):529-536. PubMed ID: 31424277
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J
    Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667
    [No Abstract]   [Full Text] [Related]  

  • 16. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients.
    Ono K; Hayashi H; Tateno M; Tanaka R; Suzuki R; Maruyama Y; Miyagi Y; Furuya M
    Int J Clin Exp Pathol; 2014; 7(11):7979-88. PubMed ID: 25550841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
    Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
    Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.